Meet the 7 startups Mayo Clinic just welcomed to its AI accelerator

August 11, 2022
MedCity News

This article was written by Katie Adams and published in MedCity News.

---

Mayo Clinic recently welcomed seven more healthcare startups to its accelerator program. In exchange for an equity position in each startup, Mayo Clinic gives young digital health companies the opportunity to refine their AI models using its deidentified data sets and subject matter experts.

Mayo Clinic on Wednesday welcomed seven more healthcare startups to its accelerator program to help young companies develop and validate their artificial intelligence-powered healthcare products.

The announcement came just months after Mayo Clinic selected the program’s initial cohort of four companies in March.

Each company participating in the 20-week program, called Mayo Clinic Platform_Accelerate, receives a $200,000-benefit package. As a condition of this investment, Mayo Clinic Platform receives an equity position in each startup.

The package allows startups to refine their AI models using Mayo Clinic’s deidentified data sets and get feedback from Mayo Clinic’s subject matter experts, including clinicians, researchers and product development professionals. It also gives startups the opportunity to attend workshops and presentations about topics ranging from FDA clearance requirements to AI ethics. Some of these workshops are led by experts from Google and Epic, according to Eric Harnisch, Mayo Clinic Platform’s vice president of partner programs.

The companies chosen for the program’s second cohort went through a selection process in which Mayo Clinic experts assessed their potential to address unmet medical needs with the use of AI. Harnisch said the team selected companies that had robust data science foundation and prior experience with Google Cloud Platform, as that is Mayo Clinic’s cloud provider.

Here are the seven startups selected:

AESOP Technology
Berkeley, California-based AESOP, which stands for AI-Enhanced Safety of Prescription, develops automation software to improve the clinical decision support process and make physician data entry faster and less error-prone. It recently launched its latest clinical documentation improvement tool, which helps medical coders flag diagnoses or procedures that were flagged incorrectly. The startup has offices in California, Colorado and Taiwan.

Biotia
New York City-based Biotia is a spinout of Cornell Tech that is focused on battling infectious diseases with AI and genomics. The company claims it is working toward developing the world’s leading microbial sequence database. It is currently creating DNA sequencing technology to allow for the personalized discovery of disease-causing microorganisms. This rapid precision infectious disease discovery would guide better patient treatment and improve health outcomes, according to the startup.

Delfina
San Francisco-based Delfina is a maternal telehealth company that remotely monitors pregnant women to assess health risks and collaborates with providers to produce a personalized care plan. The startup partners with OBGYN providers to offer its services to their patients in an effort to lower the country’s maternal mortality rate, which is the highest among all developed nations. The company also has offices in New York City and Rochester, Minnesota.

Dynocardia
Cambridge, Massachusetts-based Dynocardia uses wearable technology to track real-world continuous blood pressure and other advanced heart function measures. It created ViTrack, a cuff-less wearable that enables non-invasive blood pressure measurement and leverages AI for the early detection of heart issues to prevent serious health events.

ImpriMed
Palo Alto-based ImpriMed is aiming to validate a personalized medicine platform for human and animal cancer patients. Using AI, the startup’s platform gives patients and clinicians predictive information for personalized cancer treatment pathways, allowing oncologists to quickly identify which available drugs provide the best clinical outcomes for a particular patient. The company also has offices in Seoul.

Predicta Med
Tel Aviv-based Predicta Med offers an AI-powered decision support platform for the early detection of autoimmune diseases. Using EMRs and claims data, the company built algorithms that detect various autoimmune diseases. The startup’s platform shows clinicians which patients are at risk and provides treatment recommendations. It believes that early detection and intervention decreases health plans’ costs and strengthens treatment efficacy.

SOAP Health
Boca Raton-based SOAP Health stands for Subjective, Objective, Assessment, Plan. Its software is designed to improve early disease detection and diagnosis at the point of care. The startup offers an EHR-integrated platform with a patient and physician-facing interface that is powered by conversational AI. This platform identifies at-risk patients  who meet national medical associations’ guidelines for increased surveillance for cancer, heart disease and type 2 diabetes.

In the News

Artificial Intelligence Takes on Cancer: The Only AI Dr. Karyn Doesn’t Hate

Dogster
Learn More →

Comparative Oncology: Advances in Cancer Care from Pets to Humans

Pharmacy Times
Learn More →

Cancer Treatment Gets Personal: How Artificial Intelligence Is Taking the Guesswork Out of Common Canine Cancers

Dogster
Learn More →

Ilona Holcomb on How ImpriMed’s AI is Transforming Cancer Treatment for Pets and Humans

Biopharma Boardroom
Learn More →

From Dogs to Humans: AI-Powered Drug Response Prediction Technology Demonstrates Improved Clinical Outcomes in Oncology

Pharmacy Times
Learn More →

ImpriMed unveils cancer treatment forecast technology

MobiHealthNews
Learn More →

New research evaluates flow cytometry and PARR as diagnostic support for feline lymphoma

American Animal Hospital Association NEWStat®
Learn More →

Cell-sizing method for high-accuracy feline lymphoma characterisation in veterinary sciences

Veterinary Practice
Learn More →

Flow cytometry and clonality evaluation are effective for characterizing feline lymphoma

DVM360
Learn More →

ImpriMed: Providing Personalized Medicine For Pets With Blood Cancer Diseases In A $1+ Billion Market

Pulse 2.0
Learn More →

New AI Tool Guides Canine Cancer Treatment

Today's Veterinary Business
Learn More →

Artificial intelligence poised to transform veterinary care

AVMA News
Learn More →

New AI service offers personalized drug response predictions for canine patients with cancer

DVM360
Learn More →

Dog cancer treatment ImpriMed aims to expand its AI technology into human oncology

TechCrunch
Learn More →

ImpriMed’s Transformative, Personal Approach to Canine Cancer Treatment

USA Today
Learn More →

Data Science Can Markedly Improve Cancer Treatment Outcomes — ImpriMed Shows You How

Innovative Veterinary Care Journal
Learn More →

How ImpriMed Can Help Increase Cancer Remissions, Grow Your Reputation and Level Up Your Revenue

Innovative Veterinary Care Journal
Learn More →

ImpriMed: A Breath of Fresh Air for Traditionally Onerous Cancer Treatment Journeys

Innovative Veterinary Care Journal
Learn More →

ImpriMed: Revolutionizing Canine Cancer Treatment with Precision and Personalization

International Business Times
Learn More →

New AI Technology From ImpriMed Helps Improve Cancer Treatment Success Rates in Your Practice…and Fosters Better Relationships

Innovative Veterinary Care Journal
Learn More →

The latest and greatest in canine oncology treatment

DVM360
Learn More →

Get Rid of Your Cancer Treatment Frustrations

Innovative Veterinary Care Journal
Learn More →

Be sure to improve your cancer treatment outcomes

Innovative Veterinary Care Journal
Learn More →

Early leukemia and lymphoma remissions in cats and dogs

Innovative Veterinary Care Journal
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 3)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 2)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 1)

One Million by One Million
Learn More →

Technological advancement makes cancer treatment easier

Innovative Veterinary Care Journal
Learn More →

Novel veterinary oncologic treatments and diagnostics

dvm360
Learn More →

AI’s Computing Power Could Make Fusion Energy Practical

Lifewire
Learn More →

Don't Guess Your Pet's Condition, Treat It with ImpriMed

Startup to Follow
Learn More →

Interview with ImpriMed CEO & Co-Founder Sungwon Lim

IdeaMensch
Learn More →

This Test Might Make All The Difference When Fighting Lymphoma

Canine Cancer Alliance
Learn More →

ImpriMed: Fighting Cancer — From Dogs To Humans

Startup Thread
Learn More →

At Pear demo day, a who’s who of VCs, and plenty of fresh ideas

TechCrunch
Learn More →